Next Article in Journal
New Insights into the Role of Histone Changes in Aging
Next Article in Special Issue
ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
Previous Article in Journal
Cyclin Y Is Expressed in Platelets and Modulates Integrin Outside-in Signaling
Previous Article in Special Issue
Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Review

Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies

by 1,2 and 1,2,3,4,5,*
1
Department of Biomedical Sciences, Korea University College of Medicine, Seoul 02841, Korea
2
Institute of Human Genetics, Korea University College of Medicine, Seoul 02841, Korea
3
Department of Biomedical Sciences, Graduate School, Korea University, Seoul 02841, Korea
4
BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of Medicine, Seoul 02841, Korea
5
Biomedical Research Center, Korea University Anam Hospital, Seoul 02841, Korea
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(21), 8240; https://doi.org/10.3390/ijms21218240
Received: 12 October 2020 / Revised: 28 October 2020 / Accepted: 30 October 2020 / Published: 3 November 2020
(This article belongs to the Special Issue Recent Advances in Antibody Therapeutics)
G-protein-coupled receptors (GPCR) transmit extracellular signals into cells to regulate a variety of cellular functions and are closely related to the homeostasis of the human body and the progression of various types of diseases. Great attention has been paid to GPCRs as excellent drug targets, and there are many commercially available small-molecule chemical drugs against GPCRs. Despite this, the development of therapeutic anti-GPCR antibodies has been delayed and is challenging due to the difficulty in preparing active forms of GPCR antigens, resulting from their low cellular expression and complex structures. Here, we focus on anti-GPCR antibodies that have been approved or are subject to clinical trials and present various technologies to prepare active GPCR antigens that enable the isolation of therapeutic antibodies to proceed toward clinical validation. View Full-Text
Keywords: G protein-coupled receptor; membrane protein; antigen; therapeutic antibody G protein-coupled receptor; membrane protein; antigen; therapeutic antibody
Show Figures

Figure 1

MDPI and ACS Style

Ju, M.-S.; Jung, S.T. Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies. Int. J. Mol. Sci. 2020, 21, 8240. https://doi.org/10.3390/ijms21218240

AMA Style

Ju M-S, Jung ST. Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies. International Journal of Molecular Sciences. 2020; 21(21):8240. https://doi.org/10.3390/ijms21218240

Chicago/Turabian Style

Ju, Man-Seok, and Sang T. Jung 2020. "Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies" International Journal of Molecular Sciences 21, no. 21: 8240. https://doi.org/10.3390/ijms21218240

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop